The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

but are common on the scalp, elbows, and knees. If you have psoriasis, you may also have dry or cracked skin, which can cause itching and bleeding. In the early stages of PsA, you may see changes ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and ... symptoms for psoriasis patients and can significantly impact quality of life," said Del Campo. "Early relief can ...

In February, VYNE Therapeutics dosed the first subject in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. The clinical hold does not apply to VYNE’s ongoing Phase 2b ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid ... Pruritus reduction was reported as early as 24 hours after the first ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis ... in scalp itch, particularly, were seen in the roflumilast group as early as 24 ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study ... helped 66% of patients with scalp psoriasis and 77% of those with genital ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...